| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
CB/cannabinoid receptor
Pentadecanoyl-L-carnitine chloride targets cannabinoid CB1 and CB2 receptors, serotonin 5-HT1A and 5-HT1B receptors, and histamine H1 and H2 receptors. As a CB receptor agonist, it activates cannabinoid signaling pathways. It inhibits T cell proliferation in a primary human cell system and reduces chemokine (C-C) motif ligand 2 (CCL2) levels. |
|---|---|
| ln Vitro |
Pentadecanoyl-L-carnitine acts as a cannabinoid (CB) receptor agonist, with EC50 values of 3.7 µM for CB1 receptors and 3.2 µM for CB2 receptors in a cAMP modulation assay. The compound also functions as an agonist at serotonin receptor subtypes 5-HT1A and 5-HT1B, with EC50 values of 9.6 µM and 9.3 µM, respectively. Additionally, it serves as an antagonist at histamine H1 and H2 receptors, with EC50 values of 10.9 µM and 6.1 µM, respectively. Pentadecanoyl-L-carnitine inhibits T cell proliferation in a superantigen (SAg) primary human cell system and reduces chemokine (C-C) motif ligand 2 (CCL2) levels in a macrophage (Mphg) primary human cell system. The compound may also support mitochondrial function by facilitating fatty acid oxidation, contributing to cellular energy metabolism.
In vitro, Pentadecanoyl-L-carnitine chloride acts as a CB receptor agonist with EC50s of 3.7 and 3.2 µM for CB1 and CB2 receptors. It inhibits T cell proliferation in a primary human cell system and reduces CCL2 levels. It also acts as an agonist at serotonin 5-HT1A and 5-HT1B receptors and an antagonist at histamine H1 and H2 receptors. |
| ln Vivo |
In vivo activity data for Pentadecanoyl-L-carnitine chloride are limited. As a biochemical reagent, it is primarily used in research applications. Its activity at multiple receptor types suggests potential for further pharmacological studies. No specific in vivo data are available.
|
| Enzyme Assay |
The non-cellular assay for Pentadecanoyl-L-carnitine chloride involves assessing its binding affinity to cannabinoid CB1 and CB2 receptors, serotonin receptors, and histamine receptors. Radioligand binding assays or cAMP modulation assays can be used to determine EC50 and IC50 values. Standard receptor pharmacology protocols are followed.
|
| Cell Assay |
In vitro cell-based assays for Pentadecanoyl-L-carnitine chloride involve culturing primary human cells or cell lines expressing cannabinoid, serotonin, or histamine receptors. Cells are treated with the compound, and receptor activation is assessed by measuring downstream signaling (e.g., cAMP modulation). T cell proliferation assays and CCL2 measurement are used to assess functional effects.
|
| Animal Protocol |
In vivo animal study protocols for Pentadecanoyl-L-carnitine chloride are not well documented. As a biochemical reagent, it is primarily used in research applications. No specific animal studies have been reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Pentadecanoyl-L-carnitine chloride are not extensively characterized. It has a molecular formula of C22H44NO4·Cl and a molecular weight of approximately 422. It is a solid and should be stored at -20°C. It is slightly soluble in DMSO.
|
| Toxicity/Toxicokinetics |
Toxicological data for Pentadecanoyl-L-carnitine chloride are not extensively reported. As a research compound, it is intended for laboratory use only. Standard safety precautions should be observed during handling. The compound is not approved for human therapeutic use.
|
| References |
[1]. https://pubchem.ncbi.nlm.nih.gov/compound/88333694
|
| Additional Infomation |
Pentadecanoyl-L-carnitine chloride (CAR 15:0) is a biochemical reagent and cannabinoid receptor agonist. It also acts at serotonin and histamine receptors. It inhibits T cell proliferation and reduces CCL2 levels. It is a research compound and is not a therapeutic drug.
|
| Molecular Formula |
C22H44CLNO4
|
|---|---|
| Molecular Weight |
422.042066574097
|
| Exact Mass |
421.296
|
| CAS # |
173686-57-2
|
| PubChem CID |
88333694
|
| Appearance |
Typically exists as solids at room temperature
|
| Hydrogen Bond Donor Count |
1
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
28
|
| Complexity |
390
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[Cl-].O(C(CCCCCCCCCCCCCC)=O)[C@H](CC(=O)O)C[N+](C)(C)C
|
| InChi Key |
VAUHJRCIRYKXSR-VEIFNGETSA-N
|
| InChi Code |
InChI=1S/C22H43NO4.ClH/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-22(26)27-20(18-21(24)25)19-23(2,3)4;/h20H,5-19H2,1-4H3;1H/t20-;/m1./s1
|
| Chemical Name |
[(2R)-3-carboxy-2-pentadecanoyloxypropyl]-trimethylazanium chloride
|
| Synonyms |
L-Carnitine pentadecanoyl ester chloride; Pentadecanoyl-L-carnitine (chloride); 173686-57-2; SCHEMBL8620437; C15:0 L-carnitine, HCl salt; VAUHJRCIRYKXSR-VEIFNGETSA-N; L-Pentadecanoylcarnitine chloride; C15:0 Carnitine chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3694 mL | 11.8472 mL | 23.6944 mL | |
| 5 mM | 0.4739 mL | 2.3694 mL | 4.7389 mL | |
| 10 mM | 0.2369 mL | 1.1847 mL | 2.3694 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA